Takeda Launches TCIC Digital Healthcare Innovation Center in Chengdu, a China‑First
Takeda China, a subsidiary of Takeda Pharmaceutical Co. (TYO: 4502, NYSE: TAK), announced the official...
Takeda
Takeda Reports 3.9% YoY Revenue Decline in H1 2025, Citing Neuroscience Slump and FX Headwinds
Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) released its first‑half 2025 financial results today,...
Takeda Secures FDA Approval for VONVENDI’s Expanded Use in Adult and Pediatric VWD
Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) today confirmed that the U.S. Food and Drug...
Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition
Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) reported financial results for the first quarter of...
Takeda’s Oveporexton Meets All Endpoints in Phase 3 Narcolepsy Type 1 Trials
Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced that both Phase 3 randomized, double-blind, placebo-controlled...
Takeda Pharmaceutical Gains FDA Approval for Gammagard Liquid Erc in Primary Immunodeficiency
Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced that it has received marketing approval from...
Takeda’s Shan Guohong Departs to Join BeOne Medicines as Next Career Move
Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical (TYO: 4502) and President of Takeda...
EU Approves Pfizer and Takeda’s Adcetris in Hodgkin Lymphoma Combination Regimen
Partners Pfizer (NYSE: PFE) and Takeda (TYO: 4502) announced that the European Commission (EC) has...
Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) released its financial report for fiscal year 2024 (April...
Takeda’s Adzynma, BeiGene’s Sonrotoclax, and Avistone’s Andatinib Set for Priority Review in China
The website of China’s Center for Drug Evaluation (CDE) indicates that Takeda’s (TYO: 4502) Adzynma...
Belief BioMed and Takeda Win NMPA Approval for China’s First Hemophilia B Gene Therapy
China-based gene therapy specialist Belief BioMed Inc. and Takeda’s (NYSE: TAK, TYO: 4502) China unit...
Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its application for converting conditional to...
Takeda Partners with BridGene to Develop Immunology and Neurology Drug Candidates
Japan-based Takeda Pharmaceutical Company (NYSE: TAK, TYO: 4502) announced a partnership with US-based BridGene Biosciences,...
Takeda Reports 4.5% Revenue Growth in First Nine Months of Fiscal Year
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has released its financial results for the 9-month period...
Takeda and Fudan University’s IMI Launch AI-Based Rare Disease Screening and Diagnosis Project
Japan-headquartered Takeda (TYO: 4502) and the Intelligent Medicine Institute (IMI) at Fudan University have jointly...
Aosaikang’s Generic Livtencity Accepted for Review by China’s NMPA
China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed that a market filing for...
HutchMed to Receive Milestone Payment as Takeda’s Fruzaqla Gets Reimbursement Nod in Spain
China-based HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) is poised to receive another milestone payment...
Teva Pharmaceutical to Divest Holdings in Teva Takeda Pharma to JKI
Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced its intention to sell all holdings...
Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development
US-based Keros Therapeutics, Inc. (NASDAQ: KROS) has announced a significant licensing agreement with Japan-headquartered Takeda...
HutchMed Anticipates Milestone Payment as Takeda Launches Fruzaqla in Japan for CRC
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a milestone payment...